메뉴 건너뛰기




Volumn 14, Issue 5, 2013, Pages 578-585

Serotonergic drugs for depression and beyond

Author keywords

5HT1A; 5HT1B D; 5HT2A; 5HT2C; 5HT3; 5HT7; NET; SERT; SNRI; SSRI

Indexed keywords

AGOMELATINE; AMFEBUTAMONE; CITALOPRAM; DESVENLAFAXINE; DOPAMINE; DOPAMINE TRANSPORTER; DULOXETINE; EDIVOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; MILNACIPRAN; MIRTAZAPINE; NORADRENALIN TRANSPORTER; PAROXETINE; QUETIAPINE; SEROTONIN AGONIST; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN TRANSPORTER; SERTRALINE; TRAZODONE; VENLAFAXINE; VILAZODONE;

EID: 84876738342     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450111314050007     Document Type: Article
Times cited : (85)

References (69)
  • 1
    • 83455236602 scopus 로고    scopus 로고
    • Trends in primary care antidepressant prescribing 1995-2007: A longitudinal population database analysis
    • Lockhart P, Guthrie B. Trends in primary care antidepressant prescribing 1995-2007: a longitudinal population database analysis. Br J Gen Pract 2011; 61(590): e565-72.
    • (2011) Br J Gen Pract , vol.61 , Issue.590
    • Lockhart, P.1    Guthrie, B.2
  • 2
    • 84857666179 scopus 로고    scopus 로고
    • Pharmacotherapy of anxiety disorders: A critical review
    • Koen N, Stein DJ. Pharmacotherapy of anxiety disorders: a critical review. Dialogues Clin Neurosci 2011; 13(4): 423-37.
    • (2011) Dialogues Clin Neurosci , vol.13 , Issue.4 , pp. 423-437
    • Koen, N.1    Stein, D.J.2
  • 3
    • 42949168966 scopus 로고    scopus 로고
    • Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: A meta-analysis
    • Shah NR, Jones JB, Aperi J, Shemtov R, Karne A, Borenstein J. Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: a meta-analysis. Obstet Gynecol 2008; 111(5): 1175-82.
    • (2008) Obstet Gynecol , vol.111 , Issue.5 , pp. 1175-1182
    • Shah, N.R.1    Jones, J.B.2    Aperi, J.3    Shemtov, R.4    Karne, A.5    Borenstein, J.6
  • 5
    • 0030614953 scopus 로고    scopus 로고
    • Blockage of 5HT2C serotonin receptors by fluoxetine (Prozac)
    • Ni YG, Miledi R. Blockage of 5HT2C serotonin receptors by fluoxetine (Prozac). Proc Natl Acad Sci USA 1997; 94(5): 2036-40.
    • (1997) Proc Natl Acad Sci USA , vol.94 , Issue.5 , pp. 2036-2040
    • Ni, Y.G.1    Miledi, R.2
  • 8
    • 84856639838 scopus 로고    scopus 로고
    • Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter--a review of current understanding of its mechanism of action
    • Zhong H, Haddjeri N, Sanchez C. Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter--a review of current understanding of its mechanism of action. Psychopharmacology (Berl) 2012; 219(1): 1-13.
    • (2012) Psychopharmacology (Berl) , vol.219 , Issue.1 , pp. 1-13
    • Zhong, H.1    Haddjeri, N.2    Sanchez, C.3
  • 9
    • 0037330603 scopus 로고    scopus 로고
    • Neurotransmission of cognition, part 2. Selective NRIs are smart drugs: Exploiting regionally selective actions on both dopamine and norepinephrine to enhance cognition
    • Stahl SM. Neurotransmission of cognition, part 2. Selective NRIs are smart drugs: exploiting regionally selective actions on both dopamine and norepinephrine to enhance cognition. J Clin Psychiatry 2003; 64(2): 110-1.
    • (2003) J Clin Psychiatry , vol.64 , Issue.2 , pp. 110-111
    • Stahl, S.M.1
  • 10
    • 0037362361 scopus 로고    scopus 로고
    • Neurotransmission of cognition, part 3. Mechanism of action of selective NRIs: Both dopamine and norepinephrine increase in prefrontal cortex
    • Stahl SM. Neurotransmission of cognition, part 3. Mechanism of action of selective NRIs: both dopamine and norepinephrine increase in prefrontal cortex. J Clin Psychiatry 2003; 64(3): 230-1.
    • (2003) J Clin Psychiatry , vol.64 , Issue.3 , pp. 230-231
    • Stahl, S.M.1
  • 11
    • 0037262304 scopus 로고    scopus 로고
    • Neurotransmission of cognition, part 1, Dopamine is a hitchhiker in frontal cortex: Norepinephrine transporters regulate dopamine
    • Stahl SM. Neurotransmission of cognition, part 1, Dopamine is a hitchhiker in frontal cortex: norepinephrine transporters regulate dopamine. J Clin Psychiatry 2003; 64(1): 4-5.
    • (2003) J Clin Psychiatry , vol.64 , Issue.1 , pp. 4-5
    • Stahl, S.M.1
  • 12
    • 67649405195 scopus 로고    scopus 로고
    • Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors
    • Briley M, Moret C. Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr 2008; 13(7 Suppl 11): 22-6.
    • (2008) CNS Spectr , vol.13 , Issue.7 SUPPL. 11 , pp. 22-26
    • Briley, M.1    Moret, C.2
  • 13
    • 0029891688 scopus 로고    scopus 로고
    • Dose-response relationship with venlafaxine
    • discussion 6S-8S
    • Kelsey JE. Dose-response relationship with venlafaxine. J Clin Psychopharmacol 1996; 16(3 Suppl 2): 21S-6S; discussion 6S-8S.
    • (1996) J Clin Psychopharmacol , vol.16 , Issue.3 SUPPL. 2
    • Kelsey, J.E.1
  • 14
    • 11144231468 scopus 로고    scopus 로고
    • The role of venlafaxine in the treatment of obsessive-compulsive disorder
    • Phelps NJ, Cates ME. The role of venlafaxine in the treatment of obsessive-compulsive disorder. Ann Pharmacother 2005; 39(1): 136-40.
    • (2005) Ann Pharmacother , vol.39 , Issue.1 , pp. 136-140
    • Phelps, N.J.1    Cates, M.E.2
  • 15
    • 34250368104 scopus 로고    scopus 로고
    • Extended-release formulation of venlafaxine in the treatment of post-traumatic stress disorder
    • Pae CU, Lim HK, Ajwani N, Lee C, Patkar AA. Extended-release formulation of venlafaxine in the treatment of post-traumatic stress disorder. Expert Rev Neurother 2007; 7(6): 603-15.
    • (2007) Expert Rev Neurother , vol.7 , Issue.6 , pp. 603-615
    • Pae, C.U.1    Lim, H.K.2    Ajwani, N.3    Lee, C.4    Patkar, A.A.5
  • 16
    • 81855205290 scopus 로고    scopus 로고
    • Desvenlafaxine in the treatment of major depressive disorder
    • Pae CU. Desvenlafaxine in the treatment of major depressive disorder. Expert Opin Pharmacother 2011; 12(18): 2923-8.
    • (2011) Expert Opin Pharmacother , vol.12 , Issue.18 , pp. 2923-2928
    • Pae, C.U.1
  • 19
    • 84860612593 scopus 로고    scopus 로고
    • Treatments for diabetic neuropathy
    • Bril V. Treatments for diabetic neuropathy. J Peripher Nerv Syst 2012; 17 Suppl 2:22-7.
    • (2012) J Peripher Nerv Syst , vol.17 , Issue.SUPPL. 2 , pp. 22-27
    • Bril, V.1
  • 20
    • 84859089938 scopus 로고    scopus 로고
    • The role of antidepressants in the management of fibromyalgia syndrome: A systematic review and meta-analysis
    • Hauser W, Wolfe F, Tolle T, Uceyler N, Sommer C. The role of antidepressants in the management of fibromyalgia syndrome: a systematic review and meta-analysis. CNS Drugs 2012; 26(4): 297-307.
    • (2012) CNS Drugs , vol.26 , Issue.4 , pp. 297-307
    • Hauser, W.1    Wolfe, F.2    Tolle, T.3    Uceyler, N.4    Sommer, C.5
  • 21
    • 84856893689 scopus 로고    scopus 로고
    • A systematic review of duloxetine for osteoarthritic pain: What is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?
    • Citrome L, Weiss-Citrome A. A systematic review of duloxetine for osteoarthritic pain: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed? Postgrad Med 2012; 124(1): 83-93.
    • (2012) Postgrad Med , vol.124 , Issue.1 , pp. 83-93
    • Citrome, L.1    Weiss-Citrome, A.2
  • 22
    • 80955150217 scopus 로고    scopus 로고
    • Milnacipran: A unique antidepressant?
    • Kasper S, Pail G. Milnacipran: a unique antidepressant? Neuropsychiatr Dis Treat 2010; 6: 23-31.
    • (2010) Neuropsychiatr Dis Treat , vol.6 , pp. 23-31
    • Kasper, S.1    Pail, G.2
  • 23
    • 84876718762 scopus 로고    scopus 로고
    • Levominacipran in the treatment of major depressive disorer: An analysis of efficacy data from 2 pahse III studies
    • May 8; Philadelphia, PA
    • Bose A, Gommoll C, Li H, Rut A. Levominacipran in the treatment of major depressive disorer: an analysis of efficacy data from 2 pahse III studies. American Psychiatric Association Annual Meeting; May 8; Philadelphia, PA2012.
    • (2012) American Psychiatric Association Annual Meeting
    • Bose, A.1    Gommoll, C.2    Li, H.3    Rut, A.4
  • 24
    • 80052145818 scopus 로고    scopus 로고
    • Quetiapine extended release: Adjunctive treatment in major depressive disorder
    • Sanford M. Quetiapine extended release: adjunctive treatment in major depressive disorder. CNS Drugs 2011; 25(9): 803-13.
    • (2011) CNS Drugs , vol.25 , Issue.9 , pp. 803-813
    • Sanford, M.1
  • 25
    • 84859940784 scopus 로고    scopus 로고
    • Quetiapine: A review of its use in the management of bipolar depression
    • Sanford M, Keating GM. Quetiapine: a review of its use in the management of bipolar depression. CNS Drugs 2012; 26(5): 435-60.
    • (2012) CNS Drugs , vol.26 , Issue.5 , pp. 435-460
    • Sanford, M.1    Keating, G.M.2
  • 26
    • 79955889045 scopus 로고    scopus 로고
    • A randomized, double-blind study comparing LY2216684 and placebo in the treatment of major depressive disorder
    • Pangallo B, Dellva MA, D'Souza DN, Essink B, Russell J, Goldberger C. A randomized, double-blind study comparing LY2216684 and placebo in the treatment of major depressive disorder. J Psychiatr Res 2011; 45(6): 748-55.
    • (2011) J Psychiatr Res , vol.45 , Issue.6 , pp. 748-755
    • Pangallo, B.1    Dellva, M.A.2    D'Souza, D.N.3    Essink, B.4    Russell, J.5    Goldberger, C.6
  • 27
    • 33846003865 scopus 로고    scopus 로고
    • Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent
    • Dwoskin LP, Rauhut AS, King-Pospisil KA, Bardo MT. Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. CNS Drug Rev 2006; 12(3-4): 178-207.
    • (2006) CNS Drug Rev , vol.12 , Issue.3-4 , pp. 178-207
    • Dwoskin, L.P.1    Rauhut, A.S.2    King-Pospisil, K.A.3    Bardo, M.T.4
  • 29
    • 2442457724 scopus 로고    scopus 로고
    • Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: An [11C]DASB positron emission tomography study
    • Meyer JH, Wilson AA, Sagrati S, et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry 2004; 161(5): 826-35.
    • (2004) Am J Psychiatry , vol.161 , Issue.5 , pp. 826-835
    • Meyer, J.H.1    Wilson, A.A.2    Sagrati, S.3
  • 30
    • 77949281313 scopus 로고    scopus 로고
    • Regulation of the dopamine transporter: Aspects relevant to psychostimulant drugs of abuse
    • Schmitt KC, Reith ME. Regulation of the dopamine transporter: aspects relevant to psychostimulant drugs of abuse. Ann N Y Acad Sci 2010; 1187: 316-40.
    • (2010) Ann N Y Acad Sci , vol.1187 , pp. 316-340
    • Schmitt, K.C.1    Reith, M.E.2
  • 31
    • 0034966465 scopus 로고    scopus 로고
    • [(11)]Cocaine: PET studies of cocaine pharmacokinetics, dopamine transporter availability and dopamine transporter occupancy
    • Fowler JS, Volkow ND, Wang GJ, Gatley SJ, Logan J. [(11)]Cocaine: PET studies of cocaine pharmacokinetics, dopamine transporter availability and dopamine transporter occupancy. Nucl Med Biol 2001; 28(5): 561-72.
    • (2001) Nucl Med Biol , vol.28 , Issue.5 , pp. 561-572
    • Fowler, J.S.1    Volkow, N.D.2    Wang, G.J.3    Gatley, S.J.4    Logan, J.5
  • 32
    • 0028787766 scopus 로고
    • Bupropion: A review of its mechanism of antidepressant activity
    • Ascher JA, Cole JO, Colin JN, et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995; 56(9): 395-401.
    • (1995) J Clin Psychiatry , vol.56 , Issue.9 , pp. 395-401
    • Ascher, J.A.1    Cole, J.O.2    Colin, J.N.3
  • 33
    • 79960016570 scopus 로고    scopus 로고
    • Star-D: Lessons learned and future implications
    • Rush AJ. Star-D: lessons learned and future implications. Depress Anxiety 2011; 28(7): 521-4.
    • (2011) Depress Anxiety , vol.28 , Issue.7 , pp. 521-524
    • Rush, A.J.1
  • 34
    • 33751338530 scopus 로고    scopus 로고
    • Acute and longerterm outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report
    • Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longerterm outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163(11): 1905-17.
    • (2006) Am J Psychiatry , vol.163 , Issue.11 , pp. 1905-1917
    • Rush, A.J.1    Trivedi, M.H.2    Wisniewski, S.R.3
  • 35
    • 84858153468 scopus 로고    scopus 로고
    • Outcomes on the pharmacopsychometric triangle in bupropion-SR vs. buspirone augmentation of citalopram in the STAR*D trial
    • Bech P, Fava M, Trivedi MH, Wisniewski SR, Rush AJ. Outcomes on the pharmacopsychometric triangle in bupropion-SR vs. buspirone augmentation of citalopram in the STAR*D trial. Acta Psychiatr Scand 2012; 125(4): 342-8.
    • (2012) Acta Psychiatr Scand , vol.125 , Issue.4 , pp. 342-348
    • Bech, P.1    Fava, M.2    Trivedi, M.H.3    Wisniewski, S.R.4    Rush, A.J.5
  • 36
    • 80054867307 scopus 로고    scopus 로고
    • The efficacy and tolerability of bupropion in the treatment of major depressive disorder
    • Moreira R. The efficacy and tolerability of bupropion in the treatment of major depressive disorder. Clin Drug Investig 2011; 31 Suppl 1: 5-17.
    • (2011) Clin Drug Investig , vol.31 , Issue.SUPPL. 1 , pp. 5-17
    • Moreira, R.1
  • 37
    • 70450203499 scopus 로고    scopus 로고
    • Prospect of a dopamine contribution in the next generation of antidepressant drugs: The triple reuptake inhibitors
    • Guiard BP, El Mansari M, Blier P. Prospect of a dopamine contribution in the next generation of antidepressant drugs: the triple reuptake inhibitors. Curr Drug Targets 2009; 10(11): 1069-84.
    • (2009) Curr Drug Targets , vol.10 , Issue.11 , pp. 1069-1084
    • Guiard, B.P.1    El Mansari, M.2    Blier, P.3
  • 38
    • 79960381632 scopus 로고    scopus 로고
    • Triple reuptake inhibitors for treating subtypes of major depressive disorder: The monoamine hypothesis revisited
    • Prins J, Olivier B, Korte SM. Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited. Expert Opin Investig Drugs 2011; 20(8): 1107-30.
    • (2011) Expert Opin Investig Drugs , vol.20 , Issue.8 , pp. 1107-1130
    • Prins, J.1    Olivier, B.2    Korte, S.M.3
  • 39
    • 33748077457 scopus 로고    scopus 로고
    • Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor
    • Skolnick P, Krieter P, Tizzano J, et al. Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor. CNS Drug Rev 2006; 12(2): 123-34.
    • (2006) CNS Drug Rev , vol.12 , Issue.2 , pp. 123-134
    • Skolnick, P.1    Krieter, P.2    Tizzano, J.3
  • 40
    • 81855211117 scopus 로고    scopus 로고
    • Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: A randomized, doubleblind, placebo-controlled trial
    • Tran P, Skolnick P, Czobor P, et al. Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, doubleblind, placebo-controlled trial. J Psychiatr Res 2012; 46(1): 64-71.
    • (2012) J Psychiatr Res , vol.46 , Issue.1 , pp. 64-71
    • Tran, P.1    Skolnick, P.2    Czobor, P.3
  • 41
    • 0029885576 scopus 로고    scopus 로고
    • Adrenoceptors and serotonin receptor function: Relevance to antidepressant mechanisms of action
    • Potter WZ. Adrenoceptors and serotonin receptor function: relevance to antidepressant mechanisms of action. J Clin Psychiatry 1996; 57 Suppl 4: 4-8.
    • (1996) J Clin Psychiatry , vol.57 , Issue.SUPPL. 4 , pp. 4-8
    • Potter, W.Z.1
  • 42
    • 37049007217 scopus 로고    scopus 로고
    • Presynaptic autoreceptors regulating transmitter release
    • Langer SZ. Presynaptic autoreceptors regulating transmitter release. Neurochem Int 2008; 52(1-2): 26-30.
    • (2008) Neurochem Int , vol.52 , Issue.1-2 , pp. 26-30
    • Langer, S.Z.1
  • 43
    • 79958731767 scopus 로고    scopus 로고
    • Review of the use of mirtazapine in the treatment of depression
    • Benjamin S, Doraiswamy PM. Review of the use of mirtazapine in the treatment of depression. Expert Opin Pharmacother 2011; 12(10): 1623-32.
    • (2011) Expert Opin Pharmacother , vol.12 , Issue.10 , pp. 1623-1632
    • Benjamin, S.1    Doraiswamy, P.M.2
  • 44
    • 79951656434 scopus 로고    scopus 로고
    • Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: An 8-week open-label randomised paroxetine-controlled trial
    • Kim JE, Yoon SJ, Kim J, et al. Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial. Int J Clin Pract 2011; 65(3): 323-9.
    • (2011) Int J Clin Pract , vol.65 , Issue.3 , pp. 323-329
    • Kim, J.E.1    Yoon, S.J.2    Kim, J.3
  • 45
    • 0030915142 scopus 로고    scopus 로고
    • A comparison of the physicochemical and biological properties of mirtazapine and mianserin
    • Kelder J, Funke C, De Boer T, Delbressine L, Leysen D, Nickolson V. A comparison of the physicochemical and biological properties of mirtazapine and mianserin. J Pharm Pharmacol 1997; 49(4): 403-11.
    • (1997) J Pharm Pharmacol , vol.49 , Issue.4 , pp. 403-411
    • Kelder, J.1    Funke, C.2    de Boer, T.3    Delbressine, L.4    Leysen, D.5    Nickolson, V.6
  • 46
    • 0032510218 scopus 로고    scopus 로고
    • Effects of 5-HT1A receptor antagonists on fluoxetine-induced changes in extracellular serotonin concentrations in rat frontal cortex
    • Dawson LA, Nguyen HQ. Effects of 5-HT1A receptor antagonists on fluoxetine-induced changes in extracellular serotonin concentrations in rat frontal cortex. Eur J Pharmacol 1998; 345(1): 41-6.
    • (1998) Eur J Pharmacol , vol.345 , Issue.1 , pp. 41-46
    • Dawson, L.A.1    Nguyen, H.Q.2
  • 47
    • 84930482645 scopus 로고    scopus 로고
    • Clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use
    • Singh M, Schwartz TL. Clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use. Neuropsychiatr Dis Treat 2012; 8: 123-30.
    • (2012) Neuropsychiatr Dis Treat , vol.8 , pp. 123-130
    • Singh, M.1    Schwartz, T.L.2
  • 48
    • 0030957585 scopus 로고    scopus 로고
    • EMD 68843, a serotonin reuptake inhibitor with selective presynaptic 5-HT1A receptor agonistic properties
    • Bartoszyk GD, Hegenbart R, Ziegler H. EMD 68843, a serotonin reuptake inhibitor with selective presynaptic 5-HT1A receptor agonistic properties. Eur J Pharmacol 1997; 322(2-3): 147-53.
    • (1997) Eur J Pharmacol , vol.322 , Issue.2-3 , pp. 147-153
    • Bartoszyk, G.D.1    Hegenbart, R.2    Ziegler, H.3
  • 49
    • 0033827059 scopus 로고    scopus 로고
    • Drug action at the 5-HT(1A) receptor in vivo: Autoreceptor and postsynaptic receptor occupancy examined with PET and [carbonyl-(11)C]WAY-100635
    • Rabiner EA, Gunn RN, Wilkins MR, et al. Drug action at the 5-HT(1A) receptor in vivo: autoreceptor and postsynaptic receptor occupancy examined with PET and [carbonyl-(11)C]WAY-100635. Nucl Med Biol 2000; 27(5): 509-13.
    • (2000) Nucl Med Biol , vol.27 , Issue.5 , pp. 509-513
    • Rabiner, E.A.1    Gunn, R.N.2    Wilkins, M.R.3
  • 50
    • 33947326248 scopus 로고    scopus 로고
    • Drug evaluation: Vilazodone--a combined SSRI and 5-HT1A partial agonist for the treatment of depression
    • de Paulis T. Drug evaluation: Vilazodone--a combined SSRI and 5-HT1A partial agonist for the treatment of depression. IDrugs 2007; 10(3): 193-201.
    • (2007) IDrugs , vol.10 , Issue.3 , pp. 193-201
    • de Paulis, T.1
  • 51
    • 34548617702 scopus 로고    scopus 로고
    • Augmentation strategies for treatment-resistant depression: A literature review
    • Carvalho AF, Cavalcante JL, Castelo MS, Lima MC. Augmentation strategies for treatment-resistant depression: a literature review. J Clin Pharm Ther 2007; 32(5): 415-28.
    • (2007) J Clin Pharm Ther , vol.32 , Issue.5 , pp. 415-428
    • Carvalho, A.F.1    Cavalcante, J.L.2    Castelo, M.S.3    Lima, M.C.4
  • 52
    • 73849088753 scopus 로고    scopus 로고
    • Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression
    • Khan A. Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression. Expert Opin Investig Drugs 2009; 18(11): 1753-64.
    • (2009) Expert Opin Investig Drugs , vol.18 , Issue.11 , pp. 1753-1764
    • Khan, A.1
  • 53
    • 0032958811 scopus 로고    scopus 로고
    • Effects of SSRIs on sexual function: A critical review
    • Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol 1999; 19(1): 67-85.
    • (1999) J Clin Psychopharmacol , vol.19 , Issue.1 , pp. 67-85
    • Rosen, R.C.1    Lane, R.M.2    Menza, M.3
  • 54
    • 84997941890 scopus 로고    scopus 로고
    • Vilazodone: A brief pharmacological and clinical review of the novel serotonin partial agonist and reuptake inhibitor
    • Schwartz TL, Siddiqui UA, Stahl SM. Vilazodone: a brief pharmacological and clinical review of the novel serotonin partial agonist and reuptake inhibitor. Therapeutic Advances in Psychopharmacology 2011; 1(3): 81-7.
    • (2011) Therapeutic Advances in Psychopharmacology , vol.1 , Issue.3 , pp. 81-87
    • Schwartz, T.L.1    Siddiqui, U.A.2    Stahl, S.M.3
  • 55
    • 0028408335 scopus 로고
    • Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders
    • Haria M, Fitton A, McTavish D. Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders. Drugs Aging 1994; 4(4): 331-55.
    • (1994) Drugs Aging , vol.4 , Issue.4 , pp. 331-355
    • Haria, M.1    Fitton, A.2    McTavish, D.3
  • 56
    • 78650569849 scopus 로고    scopus 로고
    • Second-generation antipsychotics in major depressive disorder: Update and clinical perspective
    • Chen J, Gao K, Kemp DE. Second-generation antipsychotics in major depressive disorder: update and clinical perspective. Curr Opin Psychiatry 2011; 24(1): 10-7.
    • (2011) Curr Opin Psychiatry , vol.24 , Issue.1 , pp. 10-17
    • Chen, J.1    Gao, K.2    Kemp, D.E.3
  • 57
    • 33846426067 scopus 로고    scopus 로고
    • Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission
    • Alex KD, Pehek EA. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Ther 2007; 113(2): 296-320.
    • (2007) Pharmacol Ther , vol.113 , Issue.2 , pp. 296-320
    • Alex, K.D.1    Pehek, E.A.2
  • 58
    • 51149117395 scopus 로고    scopus 로고
    • Olanzapine/fluoxetine combination for treatmentresistant depression: Efficacy and clinical utility
    • Dodd S, Berk M. Olanzapine/fluoxetine combination for treatmentresistant depression: efficacy and clinical utility. Expert Rev Neurother 2008; 8(9): 1299-306.
    • (2008) Expert Rev Neurother , vol.8 , Issue.9 , pp. 1299-1306
    • Dodd, S.1    Berk, M.2
  • 59
    • 77956590945 scopus 로고    scopus 로고
    • Quetiapine: Novel uses in the treatment of depressive and anxiety disorders
    • Ravindran AV, Al-Subaie A, Abraham G. Quetiapine: novel uses in the treatment of depressive and anxiety disorders. Expert Opin Investig Drugs 2010; 19(10): 1187-204.
    • (2010) Expert Opin Investig Drugs , vol.19 , Issue.10 , pp. 1187-1204
    • Ravindran, A.V.1    Al-Subaie, A.2    Abraham, G.3
  • 60
    • 84860741260 scopus 로고    scopus 로고
    • Asenapine: A clinical review of a secondgeneration antipsychotic
    • Stoner SC, Pace HA. Asenapine: a clinical review of a secondgeneration antipsychotic. Clin Ther 2012; 34(5): 1023-40.
    • (2012) Clin Ther , vol.34 , Issue.5 , pp. 1023-1040
    • Stoner, S.C.1    Pace, H.A.2
  • 61
    • 1842764851 scopus 로고    scopus 로고
    • GABAergic modulation of 5-HT7 receptor-mediated effects on 5-HT efflux in the guineapig dorsal raphe nucleus
    • Roberts C, Thomas DR, Bate ST, Kew JN. GABAergic modulation of 5-HT7 receptor-mediated effects on 5-HT efflux in the guineapig dorsal raphe nucleus. Neuropharmacology 2004; 46(7): 935-41.
    • (2004) Neuropharmacology , vol.46 , Issue.7 , pp. 935-941
    • Roberts, C.1    Thomas, D.R.2    Bate, S.T.3    Kew, J.N.4
  • 62
    • 79954597841 scopus 로고    scopus 로고
    • Pharmacological blockade of 5-HT7 receptors as a putative fast acting antidepressant strategy
    • Mnie-Filali O, Faure C, Lambas-Senas L, et al. Pharmacological blockade of 5-HT7 receptors as a putative fast acting antidepressant strategy. Neuropsychopharmacology 2011; 36(6): 1275-88.
    • (2011) Neuropsychopharmacology , vol.36 , Issue.6 , pp. 1275-1288
    • Mnie-Filali, O.1    Faure, C.2    Lambas-Senas, L.3
  • 63
    • 84867885144 scopus 로고    scopus 로고
    • Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder
    • Baldwin DS, Hansen T, Florea I. Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder. Curr Med Res Opin 2012; 28(10): 1717-24.
    • (2012) Curr Med Res Opin , vol.28 , Issue.10 , pp. 1717-1724
    • Baldwin, D.S.1    Hansen, T.2    Florea, I.3
  • 64
    • 84863403855 scopus 로고    scopus 로고
    • Pharmacological effects of Lu AA21004: A novel multimodal compound for the treatment of major depressive disorder
    • Mork A, Pehrson A, Brennum LT, et al. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther 2012; 340(3): 666-75.
    • (2012) J Pharmacol Exp Ther , vol.340 , Issue.3 , pp. 666-675
    • Mork, A.1    Pehrson, A.2    Brennum, L.T.3
  • 65
    • 84873525387 scopus 로고    scopus 로고
    • Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters-A rat microdialysis and electrophysiology study
    • Pehrson AL, Cremers T, Betry C, et al. Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters-A rat microdialysis and electrophysiology study. Eur Neuropsychopharmacol 2012.
    • (2012) Eur Neuropsychopharmacol
    • Pehrson, A.L.1    Cremers, T.2    Betry, C.3
  • 66
    • 84887319234 scopus 로고    scopus 로고
    • A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder
    • Jain R, Mahableshwarkar AR, Jacobsen PL, Chen Y, Thase ME. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. Int J Neuropsychopharmacol 2012: 1-9.
    • (2012) Int J Neuropsychopharmacol , pp. 1-9
    • Jain, R.1    Mahableshwarkar, A.R.2    Jacobsen, P.L.3    Chen, Y.4    Thase, M.E.5
  • 67
    • 0034666574 scopus 로고    scopus 로고
    • The possible role of 5-HT(1B/D) receptors in psychiatric disorders and their potential as a target for therapy
    • Moret C, Briley M. The possible role of 5-HT(1B/D) receptors in psychiatric disorders and their potential as a target for therapy. Eur J Pharmacol 2000; 404(1-2): 1-12.
    • (2000) Eur J Pharmacol , vol.404 , Issue.1-2 , pp. 1-12
    • Moret, C.1    Briley, M.2
  • 68
    • 77950445050 scopus 로고    scopus 로고
    • The auspicious role of the 5-HT3 receptor in depression: A probable neuronal target?
    • Rajkumar R, Mahesh R. The auspicious role of the 5-HT3 receptor in depression: a probable neuronal target? J Psychopharmacol 2010; 24(4): 455-69.
    • (2010) J Psychopharmacol , vol.24 , Issue.4 , pp. 455-469
    • Rajkumar, R.1    Mahesh, R.2
  • 69
    • 84858966700 scopus 로고    scopus 로고
    • Emerging drugs for major depressive disorder
    • Connolly KR, Thase ME. Emerging drugs for major depressive disorder. Expert Opin Emerg Drugs 2012; 17(1): 105-26.
    • (2012) Expert Opin Emerg Drugs , vol.17 , Issue.1 , pp. 105-126
    • Connolly, K.R.1    Thase, M.E.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.